Effects of PKF275-055, a dipeptidyl peptidase-4 inhibitor, on the development of atherosclerotic lesions in apolipoprotein E-null mice

Metabolism: Clinical and Experimental

Volumn 61, Issue 7, 2012, Pages 974-977

  Terasaki, Michishige ^a   Nagashima, Masaharu ^a   Watanabe, Takuya ^b   Nohtomi, Kyoko ^a   Mori, Yusaku ^a   Miyazaki, Akira ^a   Hirano, Tsutomu ^a  

^a SHOWA UNIVERSITY   (Japan)

^b TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; CHOLESTEROL; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DRINKING WATER; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; LOW DENSITY LIPOPROTEIN; PKF 275055; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ATHEROSCLEROSIS; ARTICLE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; FOAM CELL; MACROPHAGE; MALE; MOUSE; NONHUMAN; PERITONEAL EXUDATE CELL; PRIORITY JOURNAL;

ADAMANTANE; ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; CHOLESTEROL; DIET, ATHEROGENIC; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FOAM CELLS; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON-LIKE PEPTIDE 1; LIPOPROTEINS, LDL; MALE; MICE; NITRILES; PLAQUE, ATHEROSCLEROTIC; PYRROLIDINES; WEIGHT LOSS;

EID: 84862128306     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2011.11.011     Document Type: Article

References (16)

1. D.C. Klonoff, J.B. Buse, and L.L. Nielsen Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years Curr Med Res Opin 24 2008 275 286 (Pubitemid 351160260)
2. T. Nystrom, M.K. Gutniak, and Q. Zhang Effects of glucagon like peptide on endothelial function in type 2 diabetes patients with stable coronary artery disease Am J Physiol Endocrinol Metab 287 2004 E1209 E1215
3. M.H. Noyan-Ashraf, M.A. Momen, and K. Ban GLP-1 agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice Diabetes 58 2009 975 983
4. R. Chilton, J. Wyatt, and S. Nandish Cardiovascular comorbidities of type 2 diabetes mellitus: defining the potential of glucagonlike peptide-1-based therapies Am J Med 124 2011 S35 S53
5. M. Nagashima, T. Watanabe, and M. Terasaki Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice Diabetologia 54 2011 2649 2659
6. Y. Shiraishi, T. Watanabe, and T. Suguro Chronic urotensin II infusion enhances macrophage foam cell formation and atherosclerosis in apolipoprotein E-knockout mice J Hypertens 26 2008 1955 1965
7. E.B. Villhauer, J.A. Brinkman, and G.B. Naderi 1-[[(3-Hydroxy-1- adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties J Med Chem 46 2003 2774 2789 (Pubitemid 36702545)
8. B. Ahrén, M.S. Winzell, and N. Wierup DPP-4 inhibition improves glucose tolerance and increases insulin and GLP-1 responses to gastric glucose in association with normalized islet topography in mice with beta-cell-specific overexpression of human islet amyloid polypeptide Regul Pept 143 2007 97 103 (Pubitemid 47212530)
9. B. Ahrén, M. Sörhede Winzell, and B. Burkey Beta-cell expression of a dominant-negative HNF-1alpha compromises the ability of inhibition of dipeptidyl peptidase-4 to elicit a long-term augmentation of insulin secretion in mice Eur J Pharmacol 521 2005 164 168 (Pubitemid 41427804)
10. M. Okazaki, and I. Hara High-performance liquid chromatography of serum lipoproteins Methods Enzymol 129 1986 57 78 (Pubitemid 16061445)
11. M. Nagashima, T. Watanabe, and M. Shichiri Chronic infusion of salusin-α and -β exerts opposite effects on macrophage foam cell formation and atherosclerosis in apolipoprotein E-deficient mice Atherosclerosis 212 2010 70 77
12. G. Xu, T. Watanabe, and Y. Iso Preventive effects of heregulin-beta1 on macrophage foam cell formation and atherosclerosis Circ Res 105 2009 500 510
13. J. Hsieh, C. Longuet, and C.L. Baker The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice Diabetologia 53 2010 552 561
14. G. Flock, L.L. Baggio, and C. Longuet Incretin receptors for glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide are essential for the sustained metabolic actions of vildagliptin in mice Diabetes 56 2007 3006 3013 (Pubitemid 350223636)
15. G.P. Fadini, E. Boscaro, and M. Albiero The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha Diabetes Care 33 2010 1607 1609
16. J. Rosenstock, M.A. Baron, and S. Dejager Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial Diabetes Care 30 2007 217 223 (Pubitemid 46198322)